A Review of Three-Year Post-Colonoscopy Colorectal Cancer (PCCRC) Rates in the Published Literature
Aine Stakelum, Alexandra Zaborowski, Brenda Murphy, Des C Winter*
Department of Colorectal Surgery,
St Vincent’s University Hospital, Elm Park, Dublin, Ireland
*Corresponding author: Des C Winter, Consultant
Colorectal Surgeon, St Vincent’s University Hospital, Elm Park, Dublin, Ireland.
Email: des.winter@gmail.com
Received
Date: 23 July, 2019; Accepted
Date: 09 August, 2019; Published
Date: 14 August, 2019
Citation: Stakelum
A, Zaborowski A, Murphy B, Winter DC (2019) A Review of Three-Year
Post-Colonoscopy Colorectal Cancer (PCCRC) Rates in the Published Literature. J
Oncol Res Ther 4: 1084. DOI: 10.29011/2574-710X.001084
Background: Although
colonoscopy remains the cornerstone of CRC screening, a small proportion of
patients who have a negative endoscopic evaluation will subsequently be
diagnosed with CRC – so termed a Post-Colonoscopy Colorectal Cancer (PCCRC).
PCCRC rate has been proposed as a critical indicator of colonoscopic quality.
Aims: This study aims to determine an accurate 3-year
PCCRC rate in a westernised population with a colorectal cancer screening
programme and to analyse secondary quality assessment indicators.
Methods: A systematic review of the literature was performed
to evaluate the rate of post-colonoscopy colorectal cancers. Two electronic
databases were searched using a considered search strategy and a number of
variables were extracted in order to determine a 3-year PCCRC rate.
Results: The search identified 2022 studies for screening. 39
studies were retrieved and reviewed in full and six studies were selected for
inclusion. The median PCCRC rate among included studies was 7.69% (IQR 6.42% -
8.2%). PCCRC is associated with older age, female sex and a high Charlson
comorbidity index. PCCRCs were more likely to be located in the proximal colon
and have a lower TNM pathological stage. Secondary quality assessment
indicators were inconsistently reported amongst studies.
Conclusion: PCCRC rate is a marker of
colonoscopic quality and reducing it increases the efficacy of endoscopy
services. The methods used to calculate and report PCCRC rate vary between
jurisdictions and care must be taken when interpreting these statistics in
order to ensure an accurate patient consent process.
1. Introduction
Colorectal cancer is
the second leading cause of cancer-related mortality, and survival rates are
markedly improved with diagnosis at an early stage [1].
It is widely accepted that the majority of colorectal cancers develop
along the adenoma-carcinoma sequence, thus providing a rationale for population-based
screening to identify pre-malignant lesions and enable timely intervention.
Colonoscopy is a widely recommended and cost-effective screening modality for
colorectal cancer and its use as part of screening programmes is known to
reduce cancer-related morbidity and mortality [2,3]. Despite this, a small proportion of patients
who have a negative endoscopic examination will subsequently be diagnosed with
CRC – so termed a Post-Colonoscopy Colorectal Cancer (PCCRC). PCCRCs occur for
a variety of reasons, including poor patient compliance or inadequate bowel
preparation, but a significant number of PCCRCs occur as a result of a
pre-existing lesion being incompletely excised or missed by the endoscopist [4,5]. Minimizing the occurrence of PCCRCs improves the
quality of a screening service and measurement of PCCRC rate allows endoscopic
units to identify and rectify performance issues. Therefore, PCCRC rate has
been proposed as a surrogate marker of endoscopic quality assurance [6,7].
PCCRC rates in the
literature vary considerably from 1.2% to 10.6% [8,9]. Whilst this may be partially due to variations
in service quality between endoscopic units, it also reflects different methods
of defining and calculating PCCRC. A variety of interval time cut-off points
are reported, with studies using a range of 3-year, 5-year and 10-year screening
intervals. The World Endoscopy Organisation’s consensus statement defines PCCRC
rate as the number of PCCRCs divided by the total number of PCCRCs plus the
number of detected cancers, expressed as a percentage
[10]. PCCRCs are more likely to occur in older comorbid females, arise
in the proximal colon and have favorable histopathologic features [11]. The aim of this review was to determine the
3-year PCCRC rate of published studies and to analyse the reported secondary
quality assessment indicators.
2. Methods
A systematic literature
search of the PubMed and Scopus electronic databases was performed using
Medical Search Headings (MeSH terms) “Colorectal cancer” AND “Colonoscopy” AND (“Interval
cancer” OR “Post-colonoscopy cancer”). The search was limited to original
articles published in the English language in the past 10 years. In order to
determine an accurate PCCRC rate of a westernised population with a colorectal
cancer screening programme, only studies from Europe and North America were
included. Data extracted from selected studies included: year of publication,
location, study design, number of patients and their baseline demographics,
method of identification, definition of PCCRC, rate of PCCRC, stage, grade and
location of CRCs, caecal intubation rate, withdrawal time and quality of bowel
preparation. Statistical analyses were performed only on the extracted data
from selected studies. Basic descriptive statistics were used to summarise the
patient, study and outcome data. The rate of PCCRC was expressed as a
percentage of the total number of detected cancers plus PCCRCs.
For this review, PCCRCs
were defined as interval CRCs diagnosed between 6 and 36 months following a
colonoscopy (i.e. false negative colonoscopy), and ‘detected CRCs’ were defined
as those diagnosed within 6 months of colonoscopy (i.e. true positive
colonoscopy). Only studies that reported a 3-year PCCRC were included. Proximal,
or right-sided colon refers to the caecum, ascending and transverse colon up to
the splenic flexure, while distal, or left-sided colon relates to the splenic
flexure, descending colon, sigmoid and rectum. A specialist endoscopist refers
to a clinician who has completed specialist training in either gastroenterology
or general surgery and is practicing at attending/consultant level.
3. Results
2022
studies were identified for screening using the aforementioned search strategy,
with six studies [8,12-16] ultimately meeting
the inclusion criteria for this review (Figure 1).
The study characteristics are outlined in Table 1.
Patient details are shown in Table 2. The majority of the studies (n=4) originated from Canada
and the USA, with two European studies [8,14] also
included. The six studies included a total of 191,971 CRCs with a colonoscopy
in the preceding 36 months, of which 14,492 were PCCRCs (Table 1), giving a 3-year PCCRC rate of 7.6% (median
7.69%; interquartile range 6.42%-8.2%). The individuals in the PCCRC cohort tended
to be older than those in the detected CRC group (mean age 72.7 years vs. 71.5
years) and were more likely to be female (49% vs. 45%) with a higher incidence
of comorbidities (Charlson Comorbidity Index [5] score
≥2 19.2% vs. 13.7%). The majority of studies used
population-based registries to collect data and as a result did not have access
to the indications for colonoscopy in the study cohorts. One study [15] conducted a retrospective chart review of PCCRC
cases and reported that 62.5% of their PCCRC cohort were in a screening
programme, with the remainder being symptomatic.
PCCRCs were more likely to be an
earlier pathological stage, with 66% reported as TNM stage I or II, compared
with 53.5% of the detected CRCs. In addition, PCCRCs were more likely to be
proximally located (51.4% vs. 39.6%). Secondary quality assessment indicators
were generally poorly reported across the included studies (Table 3). None of
the studies recorded withdrawal time or rectal retroflexion rate of the PCCRC
cohort.
4. Discussion
This review showed a PCCRC rate
of 7.6% over a 3-year time period, which is in keeping with previous published
reports [8,17]. However, it can be difficult to ascertain an accurate PCCRC
rate as the definition of PCCRC varies between institutions, as do the methods
used to calculate PCCRC. For this review, interval time period was defined as
6-36 months following index colonoscopy. Some studies define PCCRCs as those
occurring within 6-36 months of colonoscopy but preclude any endoscopic
diagnoses being labelled PCCRC, thus focusing on other diagnostic methods e.g.
radiological [18], while others necessitate an endoscopic diagnosis [13,16].
Quality assessment measures
recommended by the British Society of Gastroenterology and the Association of
Coloproctology of Great Britain and Ireland are outlined in Table 4. These
guidelines advise that endoscopic units have a target PCCRC rate of <5% at 3
years [6]. Only one of the six studies in this review met this target, and the
overall rate of 7.6% is significantly higher than recommended. At present a
lack of standardization hampers accurate assessment of PCCRC rates, emphasizing
the need for a collaborative approach in order to improve cancer prevention
strategies [19]. Secondary quality indicators were not consistently reported
across included studies. Got fried and colleagues [15] note that a significant
proportion of their reported PCCRCs were in fact due to administrative errors,
with 43% of those with inadequate bowel preparation at index colonoscopy failing
to attend for a repeat examination.
In line with previous published
reports [17], this review highlights the association between PCCRC and proximal
tumour location. The reasons underlying this are likely multifactorial.
Incomplete caecal intubation would result in inadequate surveillance of the
right colon, resulting in lesions there more likely to be missed. In addition,
right-sided colonic tumours are more likely to be associated with
Microsatellite Instability (MSI) and indeed a number of studies have demonstrated
a higher rate of MSI in post-colonoscopy CRCs [20,21]. MSI is associated with a
propensity for accelerated tumorigenesis, meaning that in some cases these
lesions may have simply not been present at the time of the index colonoscopy.
This review did not demonstrate a
significant reduction in the PCCRC rate over time (Figure 2), however the six
included studies only span a 7-year timeline and cover a range of
jurisdictions. A decline in PCCRC rate has been noted in the UK, with the
3-year PCCRC rate falling from 10.2% in 2001 to 7.3% in 2007 [8], perhaps
indicating that awareness of PCCRC rate as a quality indicator has led to an
improvement in endoscopic service provision. Where possible, the endoscopic
units should attempt to elicit the cause for a higher than average PCCRC rate
in order to make service improvements. For example, if the rate is high because
of missed lesions and inadequate colonoscopy, units can take measures to
improve endoscopic training and technique.
It is worth noting that
the term ‘Post-colonoscopy cancer rate’ is a misnomer of sorts and can be misleading
as it refers, not to the rate of CRC diagnosis following colonoscopy, but
rather to the percentage of endoscopically-diagnosed cancers that had a
negative colonoscopy in the preceding three years. It is calculated as follows:
This terminology can be
confusing to patients and care must be taken to ensure accurate interpretation
and use of these statistics during the consent process. Morris, et al. note
that a more patient-centric denominator might be the total number of
colonoscopies, including true negatives, over a three-year period [8]. Using results outlined above and assuming a
colonoscopy cancer detection rate of 1%, the risk of PCCRC would be in the
order of 0.076% for all colonoscopies performed in a unit. Adherence to the
recommended methods [10] of calculating and
reporting PCCRC rate among endoscopy units will enable comparability between
services and ultimately maximise the benefit of screening programmes.
Financial Support: None
Disclosures: The
authors have no relevant financial disclosures or conflicts of interest.
Figure 1: PRISMA diagram showing selection of studies for inclusion.
Figure 2: PCCRC rate of included studies over time.
Reference |
Year
|
Location |
Study
Design |
Definition
PCCRC |
Detected
CRCS |
No
of PCCRCs |
PCCRC
RATE (%) |
Baxter |
2011 |
Canada |
Retrospective cohort |
3 years |
12,804 |
1,260 |
8.96 |
Cooper |
2011 |
USA |
Population-based
cohort |
3 years |
53,647 |
4,192 |
7.25 |
Forsberg |
2017 |
Sweden |
Population-based
cohort |
3 years |
15,033 |
1,286 |
7.88 |
Gotfried |
2015 |
USA |
Retrospective cohort |
3 years |
1,102 |
45 |
3.92 |
Morris |
2014 |
UK |
Population-based
cohort |
3 years |
90,398 |
7,321 |
7.49 |
Singh |
2010 |
Canada |
Population-based
cohort |
3 years |
4,495 |
388 |
7.95 |
TOTAL |
|
|
|
|
177,479 |
14,492 |
7.60% |
CRC = colorectal
cancer; PCCRC = post-colonoscopy colorectal cancer; PCCRC = (number of
PCCRCs) / (number of PCCRCs + number of detected CRCs) |
Reference |
No
of patients (% men) |
Median
age (years) |
CCI
high (≥2) |
Proximal
location (%) |
Early
Stage (ie TNM I + II) (%) |
|||||
|
PCCRC |
Detected |
PCCRC |
Detected |
PCCRC |
Detected |
PCCRC |
Detected |
PCCRC |
Detected |
Baxter |
1,260 (52.7) |
12,804 (56.7) |
71 |
68 |
130 (10.3) |
634 (5) |
676 (53.7) |
4,796 (37.4) |
NR |
NR |
Cooper |
4,192 (43.4) |
23,585 (44) |
3,085 >74 (74) |
38,221 >74 (71) |
908 (21.5) |
7,870 (10.7) |
2,851 (68) |
25,870 (48.2) |
2,444 (58.3) |
29,172 (54.38) |
Forsberg |
1,286 (48.7) |
15,033 (53.2) |
749 >70 (58) |
8,563 >70 (57) |
NR |
NR |
606 (47.1) |
5,877 (39.1) |
NR |
NR |
Gotfried |
24 (37.5) |
1,123 (NR) |
69 |
NR |
NR |
NR |
13 (54.2) |
NR |
13 (54.17) |
NR |
Morris |
7,321 (53.3) |
90,398 (57) |
73 |
72 |
1,540 (21) |
13,923 (15.4) |
3,077 (42) |
34,040 (37.7) |
2,630/ 5,121 cases
(73.4) |
38,339/ 71,934 cases
(53.3%) |
Singh |
388 (50.5) |
4,495 (57.5) |
NR |
NR |
55 |
938 (20.9) |
225 (58) |
1,758 (39.1) |
70/137 cases (51.1) |
727/ 1,396 cases
(52.1) |
TOTAL |
14,492
(50%) |
147,438
(55%) |
72.7 |
71.5 |
19.50% |
13.70% |
51.40% |
39.60% |
66% |
53.50% |
CCI = Charlson
Comorbidity Index; PCCRC = Post-Colonoscopy Colorectal Cancer; NR = Not
Recorded; TNM = Tumour, Node, Metastasis staging system |
Reference |
Caecal
intubation rate (%) |
Adequate
bowel preparation (%) |
rectal
retro-flexion (%) |
withdrawal
time |
colonoscopies
per annum |
pccrc
rate (%) |
Baxter |
87.6 |
NR |
NR |
NR |
129 |
8.96 |
Cooper |
NR |
NR |
NR |
NR |
≤85 – 50.1% |
7.25 |
>85 – 49.9% |
||||||
Forsberg |
NR |
NR |
NR |
NR |
NR |
7.88 |
Gotfried |
NR |
Poor – 11.1%* |
NR |
NR |
NR |
3.92 |
Good/Excellent – 72.2%* |
||||||
Morris |
NR |
NR |
NR |
NR |
NR |
7.49 |
Singh |
NR |
NR |
NR |
NR |
<259 – 47.8% |
7.95 |
≥260 – 52.2% |
||||||
NR = Not Recorded;
PCCRC = Post-Colonoscopy Colorectal Cancer Rate. *Data refers to PCCRC
cohort only. |
QUALITY ASSESSMENT
INDICATOR |
MINIMUM STANDARD |
ACHIEVABLE STANDARD |
Caecal
intubation rate |
>90% |
>95% |
Adenoma
detection rate |
>15% |
>20% |
Adequate
bowel preparation |
>90% |
>95% |
Rectal
retroflexion |
>90% |
100% |
Colonoscopy
withdrawal time |
6 minutes for negative procedures |
10 minutes for negative procedures |
colonoscopies
per annum |
Achieving competency: >200 |
|
|
Maintaining competency: >100 |
|
PCCRC
Rate |
<5% at 3 years |
|
[6] PCCRC = Post-Colonoscopy
Colorectal Cancer. |
- Allemani C, Rachet B, Weir
HK, Richardson LC, Lepage C, et al. (2013) Colorectal cancer survival in the
USA and Europe: a CONCORD high-resolution study. BMJ Open. 3: e003055.
- Winawer SJ, Zauber AG, Ho
MN, O'Brien MJ, Gottlieb LS, et al. (1993) Prevention of colorectal cancer by
colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:
1977-1981.
- Baxter NN, Warren JL,
Barrett MJ, Stukel TA, Doria-Rose VP (2012) Association between colonoscopy and
colorectal cancer mortality in a US cohort according to site of cancer and
colonoscopist specialty. J Clin Oncol 30: 2664-2669.
- le Clercq CM, Bouwens MW,
Rondagh EJ, Bakker CM, Keulen ET, et al. (2014) Postcolonoscopy colorectal
cancers are preventable: a population-based study. Gut: 957-963.
- Erichsen R, Baron JA,
Stoffel EM, Laurberg S, Sandler RS, et al. (2013) Characteristics and survival
of interval and sporadic colorectal cancer patients: a nationwide
population-based cohort study. Am J Gastroenterol 108: 1332-1340.
- Rees
CJ, Thomas Gibson S, Rutter MD, Baragwanath P, Pullan R, et al. (2016) UK key
performance indicators and quality assurance standards for colonoscopy. Gut 65:
1923-1929.
- Rex DK, Johnson DA,
Anderson JC, Schoenfeld PS, Burke CA, et al. (2009) American College of
Gastroenterology guidelines for colorectal cancer screening 2009. Am J
Gastroenterol 104: 739-750.
- Morris EJ, Rutter MD, Finan
PJ, Thomas JD, Valori R (2015) Post-colonoscopy colorectal cancer (PCCRC) rates
vary considerably depending on the method used to calculate them: a
retrospective observational population-based study of PCCRC in the English
National Health Service. Gut 64: 1248-1256.
- Iwatate M,
Kitagawa T, Katayama Y, Tokutomi N, Bane S, et al. (2017) Post-colonoscopy colorectal cancer rate in the era
of high-definition colonoscopy. World J Gastroenterol 23: 7609-7617.
- Rutter MD, Beintaris I,
Valori R, Chiu HM, Corley DA, et al. (2018) World Endoscopy Organization
Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer.
Gastroenterology 155: 909-925.
- Singh S, Singh PP, Murad
MH, Singh H, Samadder NJ (2014) Prevalence, risk factors, and outcomes of
interval colorectal cancers: a systematic review and meta-analysis. Am J
Gastroenterol 109: 1375-1389.
- Baxter NN, Sutradhar R,
Forbes SS, Paszat LF, Saskin R, et al. (2011) Analysis of administrative data
finds endoscopist quality measures associated with postcolonoscopy colorectal
cancer. Gastroenterology 140: 65-72.
- Cooper GS, Xu F, Barnholtz
Sloan JS, Schluchter MD, Koroukian SM (2012) Prevalence and predictors of
interval colorectal cancers in medicare beneficiaries. Cancer 118: 3044-3052.
- Forsberg A, Hammar U, Ekbom
A, Hultcrantz R (2017) Post-colonoscopy colorectal cancers in Sweden: room for
quality improvement. Eur J Gastroenterol Hepatol 29: 855-860.
- Gotfried J, Bernstein M,
Ehrlich AC, Friedenberg FK (2015) Administrative Database Research
Overestimates the Rate of Interval Colon Cancer. J Clin Gastroenterol 49: 483-490.
- Singh H, Nugent Z, Demers
AA, Bernstein CN (2010) Rate and predictors of early/missed colorectal cancers
after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol 105:
2588-2596.
- Nally DM, Ballester AW,
Valentelyte G, Kavanagh DO (2019) The contribution of endoscopy quality
measures to the development of interval colorectal cancers in the screening
population: a systematic review. Int J Colorectal Dis 34: 123-140.
- Bressler B, Paszat LF, Chen
Z, Rothwell DM, Vinden C, et al. (2007) Rates of new or missed colorectal
cancers after colonoscopy and their risk factors: a population-based analysis.
Gastroenterology 132: 96-102.
- Hamada T,
Nishihara R, Ogino S (2017) Post-colonoscopy colorectal cancer: the key role of
molecular pathological epidemiology. Transl Gastroenterol Hepatol 2: 9.
- Sawhney MS, Farrar WD,
Gudiseva S, Nelson DB, Lederle FA, et al. (2006) Microsatellite instability in
interval colon cancers. Gastroenterology 131: 1700-1705.
- Samadder NJ, Neklason D,
Snow A, Samowitz W, Cessna MH, et al. (2019) Clinical and Molecular Features of
Post-Colonoscopy Colorectal Cancers. Clin Gastroenterol Hepatol.